PIPER LDL
Commercial- Indications
- Hypercholesterolemia
Company intelligence / Profile preview
Piper Biosciences has developed plant sterol-based gummies clinically shown to lower LDL cholesterol. Their products are used in real-world settings and have been evaluated in clinical trials, including a Phase 4 study with Stanford University targeting South Asian patients at low-to-moderate cardiovascular risk. The company’s approach combines physician-recommended supplements with lifestyle guidance. Their main product delivers 1.14 grams of plant sterol esters per serving and is recommended by preventive cardiologists at academic lipid centers.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Piper Biosciences.